SenesTech, Inc.

NasdaqCM SNES

SenesTech, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2024: USD -6.73 M

SenesTech, Inc. Operating Income is USD -6.73 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 17.41% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

SenesTech, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -8.15 M, a 18.68% change year over year.
SenesTech, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -10.02 M, a -17.69% change year over year.
SenesTech, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -8.51 M, a 4.41% change year over year.
SenesTech, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -8.90 M, a 9.89% change year over year.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

NasdaqCM: SNES

SenesTech, Inc.

CEO	Mr. Joel L. Fruendt
IPO Date	Dec. 8, 2016
Location	United States
Headquarters	23460 North 19th Avenue
Employees	25
Sector	Health Care
Industries Biotechnology Agriculture Pharmaceuticals

Description

SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. It offers ContraPest, a liquid bait that limits reproduction of male and female rats. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.

Key trends

Past 5 years